SANTA BARBARA, Calif., Oct. 31, 2013 /PRNewswire/ -- VG Life Sciences, Inc. is a publicly traded (VGLS) biotechnology company focused on developing treatments for patients suffering autoimmune and infectious diseases.
The United States Patent and Trademark Office has issued on October 15, 2013 Patent No.: US 8,557,764 covering the VG Life Sciences' peptide VG1177 for treating HIV infection. The VG1177 peptide prevents the survival of pro-inflammatory cells under conditions where inflammation is unwanted, thereby allowing the body's natural containment systems to provide protection from harm.
The hallmarks of chronic HIV infections are chronic inflammation and loss of CD4 T cells. Thus this patent may have important implications for treating inflammation associated with HIV infection and AIDS.
The patent will be issued to the University of Colorado (CU) and has been licensed exclusively to VG Life Sciences as a result of the invention filed by VG Life Sciences' Lead Scientist, Dr. M. Karen Newell Rogers, PhD, during her tenure at the University of Colorado Colorado Springs. Dr. Newell Rogers is currently at Texas A&M University College of Medicine and Baylor Scott and White Health Care.
The patent abstract reads as follows:
"The invention relates to methods for modulating the immune function through targeting of CLIP molecules as well as gamma delta T cells. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject."
John Tynan, VG Life Sciences' President and CEO said, "First, this is a great recognition of Dr. Newell Rogers' hard work and ground breaking research. Second, this reflects our commitment to expand and secure our IP portfolio."
About VG Life Sciences Inc.
Santa Barbara, California-based VG Life Sciences Inc., formerly known as Viral Genetics, is a biotechnology company working on discovering and developing drug therapies for infectious diseases, cancer and many autoimmune diseases. VGLS controls over 50 US and international patents and patents pending protecting its exclusive biotech platform technologies. For more information and upcoming events, visit www.vglifesciences.com or find VG Life Sciences, Inc. on Facebook, Twitter, and LinkedIn.
Safe Harbor Statement and Forward-Looking Statements
This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences' drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences or any other person that the objectives and plans of VG Life Sciences will be achieved.
Alexandria Sumner, Director of Corporate Communications
VG Life Sciences, Inc.
Phone: (805) 679-6763
SOURCE VG Life Sciences, Inc.